ID

23652

Description

Responsible Party: Millennium Pharmaceuticals, Inc. ClinicalTrials.gov Identifier: NCT02038647 History of Changes Other Study ID Numbers: C14018 2013-003713-18 ( EudraCT Number ) U1111-1154-9805 ( Registry Identifier: WHO ) DRKS00007849 ( Registry Identifier: DRKS ) Study First Received: December 4, 2013 Last Updated: March 30, 2017 Phase 2 Study of Alisertib (MLN8237) in Combination With Paclitaxel Versus Placebo in Combination With Paclitaxel as Second Line Therapy for Small Cell Lung Cancer (SCLC) ODM derived from: https://clinicaltrials.gov/ct2/show/NCT02038647

Link

https://clinicaltrials.gov/ct2/show/NCT02038647

Keywords

Versions (1)
  1. 7/10/17 7/10/17 -
Uploaded on

July 10, 2017

DOI

To request one please log in.

License

Creative Commons BY 4.0
Model comments :

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Back to model comments
Itemgroup comments for :

Item comments for :

In order to download data models you must be logged in. Please log in or register for free.

Eligibility Small Cell Lung Cancer NCT02038647 DRKS00007849

English

Eligibility Small Cell Lung Cancer NCT02038647 DRKS00007849

1 forms  
Inclusion Criteria
Description

Inclusion Criteria

Alias
UMLS CUI-1
C1512693
1. Male or female participants ≥ 18 years old.
Description

Age

Data type

boolean

Alias
UMLS CUI [1]
C0001779
2. Have a pathologically (histology or cytology) confirmed diagnosis of SCLC.
Description

Small Cell Lung Cancer

Data type

boolean

Alias
UMLS CUI [1]
C0149925
3. Have received and progressed after a platinum-based standard chemotherapy regimen for first line treatment of SCLC, either limited stage (LS) or extensive stage (ES).
Description

Chemotherapy Regimen

Data type

boolean

Alias
UMLS CUI [1]
C0392920
4. Have measurable disease within ≤ 2 weeks before randomization. Clear radiographic evidence of disease progression after initial therapy should have been documented.
Description

Measurable disease

Data type

boolean

Alias
UMLS CUI [1]
C1513041
5. Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1 (PS 0-1).
Description

ECOG Performance Status

Data type

boolean

Alias
UMLS CUI [1]
C1520224
6. Participants with treated brain metastases (surgery, whole or stereotactic brain radiation) are allowed provided the lesions have been stable for at least 2 weeks and the participant is off steroids or is on a stable dose of steroids. Participants should be without neurologic dysfunction that would confound the evaluation of neurological and/or other AEs.
Description

Brain metastases

Data type

boolean

Alias
UMLS CUI [1]
C0220650
Exclusion Criteria
Description

Exclusion Criteria

Alias
UMLS CUI-1
C0680251
0. Healthy Volunteers
Description

Control Group

Data type

boolean

Alias
UMLS CUI [1]
C0009932
1. Any prior therapy for second-line treatment of SCLC.
Description

Prior Therapy

Data type

boolean

Alias
UMLS CUI [1]
C1514463
2. Participants who relapsed ≥ 180 days after their response to first-line treatment.
Description

Relapse

Data type

boolean

Alias
UMLS CUI [1]
C0277556
3. Prior treatment with an Aurora A specific-targeted or pan-Aurora-targeted agent, including alisertib, or any other investigational agent.
Description

Investigational Drug

Data type

boolean

Alias
UMLS CUI [1]
C0013230
4. Prior treatment with paclitaxel or any other taxane agent.
Description

Paclitaxel

Data type

boolean

Alias
UMLS CUI [1]
C0144576
5. Known hypersensitivity to Cremophor® EL, paclitaxel, or its components.
Description

Hypersensitivity to Paclitaxel

Data type

boolean

Alias
UMLS CUI [1,1]
C0020517
UMLS CUI [1,2]
C0215136
6. Any comorbid condition or unresolved toxicity that would preclude administration of alisertib or weekly paclitaxel.
Description

Comorbidity, Toxicity

Data type

boolean

Alias
UMLS CUI [1]
C0009488
UMLS CUI [2]
C0013221
7. Prior history of ≥ Grade 2 neurotoxicity that is not resolved to ≤ Grade 1.
Description

Neurotoxicity

Data type

boolean

Alias
UMLS CUI [1]
C0235032
8. Participants with symptomatic and/or progressive brain metastases or with carcinomatous meningitis.
Description

Brain metastases or carcinomatous meningitis

Data type

boolean

Alias
UMLS CUI [1]
C0220650
UMLS CUI [2]
C0220654
9. Treatment with clinically significant enzyme inducers within 14 days prior to the first dose of alisertib and during study conduct. Major prohibited enzyme inducers include: phenytoin, carbamazepine, phenobarbital, rifampin, rifabutin, rifapentine, and St. John's wort.
Description

Enzyme inducers

Data type

boolean

Alias
UMLS CUI [1]
C3819045
10. Inability to swallow alisertib or other orally administered medications.
Description

Ability to swallow

Data type

boolean

Alias
UMLS CUI [1]
C0566355
11. Requirement for administration of proton pump inhibitor (PPI), H2 antagonist, or pancreatic enzymes.
Description

Proton pump inhibitor, H2 antagonist, or pancreatic enzymes

Data type

boolean

Alias
UMLS CUI [1]
C0358591
UMLS CUI [2]
C0019593
UMLS CUI [3]
C0920330
12. Diagnosed with or treated for another malignancy within 2 years before the first dose of study drug, or previously diagnosed with another malignancy and have any evidence of residual disease.
Description

Malignancy

Data type

boolean

Alias
UMLS CUI [1]
C0006826
13. Other severe acute or chronic medical or psychiatric condition(s) per protocol.
Description

Mental disorder

Data type

boolean

Alias
UMLS CUI [1]
C0004936
14. History of myocardial infarction, unstable symptomatic ischemic heart disease, uncontrolled hypertension despite appropriate medical therapy, any ongoing cardiac arrhythmias of Grade > 2, thromboembolic events (eg, deep vein thrombosis, pulmonary embolism, or symptomatic cerebrovascular events), or any other cardiac condition (eg, pericardial effusion or restrictive cardiomyopathy) within 6 months before receiving the first dose of study drug.
Description

Comorbidity

Data type

boolean

Alias
UMLS CUI [1]
C0009488
15. Known history of human immunodeficiency virus (HIV) infection, hepatitis B or hepatitis C.
Description

HIV, HBV, HCV

Data type

boolean

Alias
UMLS CUI [1]
C0019699
UMLS CUI [2]
C0149709
UMLS CUI [3]
C1112419
16. Surgery within 3 weeks (or 2 weeks for a minor surgery) before study enrollment and not fully recovered to baseline or to a stable clinical status
Description

Surgery

Data type

boolean

Alias
UMLS CUI [1]
C0543467
17. Participants who are pregnant, lactating, or do not agree to use effective methods of contraception during the study treatment period through 6 months after the last dose of study drug per protocol.
Description

Gynaecological Status

Data type

boolean

Alias
UMLS CUI [1]
C0032961
UMLS CUI [2]
C0006147
UMLS CUI [3]
C0700589
Back to the top of the page

Similar models

Eligibility Small Cell Lung Cancer NCT02038647 DRKS00007849

1 forms
Name
Type
Description | Question | Decode (Coded Value)
Data type
Alias
Item Group
Inclusion Criteria
C1512693 (UMLS CUI-1)
Age
Item
1. Male or female participants ≥ 18 years old.
boolean
C0001779 (UMLS CUI [1])
Small Cell Lung Cancer
Item
2. Have a pathologically (histology or cytology) confirmed diagnosis of SCLC.
boolean
C0149925 (UMLS CUI [1])
Chemotherapy Regimen
Item
3. Have received and progressed after a platinum-based standard chemotherapy regimen for first line treatment of SCLC, either limited stage (LS) or extensive stage (ES).
boolean
C0392920 (UMLS CUI [1])
Measurable disease
Item
4. Have measurable disease within ≤ 2 weeks before randomization. Clear radiographic evidence of disease progression after initial therapy should have been documented.
boolean
C1513041 (UMLS CUI [1])
ECOG Performance Status
Item
5. Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1 (PS 0-1).
boolean
C1520224 (UMLS CUI [1])
Brain metastases
Item
6. Participants with treated brain metastases (surgery, whole or stereotactic brain radiation) are allowed provided the lesions have been stable for at least 2 weeks and the participant is off steroids or is on a stable dose of steroids. Participants should be without neurologic dysfunction that would confound the evaluation of neurological and/or other AEs.
boolean
C0220650 (UMLS CUI [1])
Item Group
Exclusion Criteria
C0680251 (UMLS CUI-1)
Control Group
Item
0. Healthy Volunteers
boolean
C0009932 (UMLS CUI [1])
Prior Therapy
Item
1. Any prior therapy for second-line treatment of SCLC.
boolean
C1514463 (UMLS CUI [1])
Relapse
Item
2. Participants who relapsed ≥ 180 days after their response to first-line treatment.
boolean
C0277556 (UMLS CUI [1])
Investigational Drug
Item
3. Prior treatment with an Aurora A specific-targeted or pan-Aurora-targeted agent, including alisertib, or any other investigational agent.
boolean
C0013230 (UMLS CUI [1])
Paclitaxel
Item
4. Prior treatment with paclitaxel or any other taxane agent.
boolean
C0144576 (UMLS CUI [1])
Hypersensitivity to Paclitaxel
Item
5. Known hypersensitivity to Cremophor® EL, paclitaxel, or its components.
boolean
C0020517 (UMLS CUI [1,1])
C0215136 (UMLS CUI [1,2])
Comorbidity, Toxicity
Item
6. Any comorbid condition or unresolved toxicity that would preclude administration of alisertib or weekly paclitaxel.
boolean
C0009488 (UMLS CUI [1])
C0013221 (UMLS CUI [2])
Neurotoxicity
Item
7. Prior history of ≥ Grade 2 neurotoxicity that is not resolved to ≤ Grade 1.
boolean
C0235032 (UMLS CUI [1])
Brain metastases or carcinomatous meningitis
Item
8. Participants with symptomatic and/or progressive brain metastases or with carcinomatous meningitis.
boolean
C0220650 (UMLS CUI [1])
C0220654 (UMLS CUI [2])
Enzyme inducers
Item
9. Treatment with clinically significant enzyme inducers within 14 days prior to the first dose of alisertib and during study conduct. Major prohibited enzyme inducers include: phenytoin, carbamazepine, phenobarbital, rifampin, rifabutin, rifapentine, and St. John's wort.
boolean
C3819045 (UMLS CUI [1])
Ability to swallow
Item
10. Inability to swallow alisertib or other orally administered medications.
boolean
C0566355 (UMLS CUI [1])
Proton pump inhibitor, H2 antagonist, or pancreatic enzymes
Item
11. Requirement for administration of proton pump inhibitor (PPI), H2 antagonist, or pancreatic enzymes.
boolean
C0358591 (UMLS CUI [1])
C0019593 (UMLS CUI [2])
C0920330 (UMLS CUI [3])
Malignancy
Item
12. Diagnosed with or treated for another malignancy within 2 years before the first dose of study drug, or previously diagnosed with another malignancy and have any evidence of residual disease.
boolean
C0006826 (UMLS CUI [1])
Mental disorder
Item
13. Other severe acute or chronic medical or psychiatric condition(s) per protocol.
boolean
C0004936 (UMLS CUI [1])
Comorbidity
Item
14. History of myocardial infarction, unstable symptomatic ischemic heart disease, uncontrolled hypertension despite appropriate medical therapy, any ongoing cardiac arrhythmias of Grade > 2, thromboembolic events (eg, deep vein thrombosis, pulmonary embolism, or symptomatic cerebrovascular events), or any other cardiac condition (eg, pericardial effusion or restrictive cardiomyopathy) within 6 months before receiving the first dose of study drug.
boolean
C0009488 (UMLS CUI [1])
HIV, HBV, HCV
Item
15. Known history of human immunodeficiency virus (HIV) infection, hepatitis B or hepatitis C.
boolean
C0019699 (UMLS CUI [1])
C0149709 (UMLS CUI [2])
C1112419 (UMLS CUI [3])
Surgery
Item
16. Surgery within 3 weeks (or 2 weeks for a minor surgery) before study enrollment and not fully recovered to baseline or to a stable clinical status
boolean
C0543467 (UMLS CUI [1])
Gynaecological Status
Item
17. Participants who are pregnant, lactating, or do not agree to use effective methods of contraception during the study treatment period through 6 months after the last dose of study drug per protocol.
boolean
C0032961 (UMLS CUI [1])
C0006147 (UMLS CUI [2])
C0700589 (UMLS CUI [3])
Back to the top of the page 

Contact

Please use this form for feedback, questions and suggestions for improvements.

Fields marked with * are required.

Help

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial